Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 29, 2018 - Issue 6
Submit an article Journal homepage
236
Views
2
CrossRef citations to date
0
Altmetric
Treatments

Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea

Sidharth SonthaliaDepartment of Dermatology & Dermatosurgery, Skinnocence: The Skin Clinic & Research Center, Gurugram, India; Correspondence[email protected]
,
Akshy KumarDepartment of Dermatology & STD, Kota Medical College, Kota, India;
,
Vijay ZawarDepartment of Dermatology & Leprosy, Dr Vasantrao Pawar Medical College, Nashik, India;
,
Adity PriyaDepartment of Community Medicine, Hind Institute of Medical Sciences, Lucknow, India;
,
Pravesh YadavDepartment of Dermatology & STD, Lady Hardinge Medical College & Associated Hospitals, New Delhi, India;
,
Sakshi SrivastavaDepartment of Dermatology & Plastic Surgery, JAYPEE Hospital, Noida-NCR, India;
&
Atula GuptaSkin-Aid Clinic, Gurugram, India
 show all
Pages 617-622 | Received 09 Dec 2017, Accepted 04 Jan 2018, Published online: 01 Feb 2018

References

  • Cheong WK, Wong KS. An epidemiological study of pityriasis rosea in middle road hospital. Singapore Med J. 1989;30:60–62.
  • Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol. 2009;61:303–318.
  • Drago F, Ciccarese G, Rebora A, et al. Relapsing pityriasis rosea. Dermatology. 2014;229:316–318.
  • Zawar V, Kumar R. Multiple recurrences of pityriasis rosea of Vidal: a novel presentation. Clin Exp Dermatol. 2009;34:e114–e116.
  • Sankararaman S, Velayuthan S. Multiple recurrences in pityriasis rosea - a case report with review of the literature. Indian J Dermatol. 2014;59:316.
  • Chuh A, Zawar V, Lee A. Atypical presentations of pityriasis rosea: case presentations. J Eur Acad Dermatol Venereol. 2005;19:120–126.
  • Ciccarese G, Broccolo F, Rebora A, et al. Oropharyngeal lesions in pityriasis rosea. J Am Acad Dermatol. 2017;77:833–837.e4.
  • Drago F, Ciccarese G, Broccolo F, et al. Pityriasis rosea in children: clinical features and laboratory investigations. Dermatology. 2015;231:9–14.
  • Zawar V. Oligo-lesional eruptions rapidly following a herald plaque: abortive pityriasis rosea. Indian J Dermatol. 2011;56:450–451.
  • Chuh AA, Chiu SS, Peiris JS. Human herpesvirus 6 and 7 DNA in peripheral blood leucocytes and plasma in patients with pityriasis rosea by polymerase chain reaction: a prospective case control study. Acta Derm Venereol. 2001;81:289–290.
  • Drago F, Ciccarese G, Rebora A, et al. Pityriasis rosea: a comprehensive classification. Dermatology. 2016;232:431–437.
  • Drago F, Ciccarese G, Broccolo F, et al. The role of cytokines, chemokines, and growth factors in the pathogenesis of pityriasis rosea. Mediators Inflamm. 2015;2015:438963.
  • Gangemi S, Cannavò SP, Guarneri F, et al. The CX3C-chemokine fractalkine (CX3CL1) is detectable in serum of patients affected by active pityriasis rosea. J Eur Acad Dermatol Venereol. 2006;20:1366–1367.
  • Watanabe T, Kawamura T, Jacob SE, et al. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. J Invest Dermatol. 2002;119:793–797.
  • Chuh AA, Dofitas BL, Comisel GG, et al. Interventions for pityriasis rosea. Cochrane Database Syst Rev. 2007;18:CD005068.
  • Neoh CY, Tan AWH, Mohamed K, et al. Characterization of the inflammatory cell infiltrate in herald patches and fully developed eruptions of pityriasis rosea. Clin Exp Dermatol. 2010;35:300–304.
  • El-Ela MA, El-Komy M, Hay RA, et al. Higher expression of toll-like receptors 3, 7, 8, and 9 in pityriasis rosea. J Pathol Transl Med. 2017;51:148–151.
  • Lim SH, Kim SM, Oh BH, et al. Low-dose ultraviolet A1 phototherapy for treating pityriasis rosea. Ann Dermatol. 2009;21:230–236.
  • Arndt KA, Paul BS, Stern RS, et al. Treatment of pityriasis rosea with UV radiation. Arch Dermatol. 1983;119:381–382.
  • Lazaro-Medina A, Villena-Amurao C, Dy-Chua NS, et al. A clinicohistopathologic study of a randomized double-blind clinical trial using oral dexchlorpheniramine 4 mg, betamethasone 500 mcg and betamethasone 250 mcg with dexchlorpheniramine 2 mg in the treatment of pityriasis rosea: a preliminary report. J Philippine Dermatol Soc. 1996;5:3–7.
  • World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.
  • Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92:497–501.
  • Leenutaphong V, Jiamton S. UVB phototherapy for pityriasis rosea: a bilateral comparison study. J Am Acad Dermatol. 1995;33:996–999.
  • Bjornberg A, Hellgren L. Pityriasis rosea. A statistical, clinical and laboratory investigation of 826 patients and matched healthy controls. Acta Dermat-Venereol. 1962;42:50.
  • Chuh AAT, Chan HHL. The effect on quality of life in patients with pityriasis rosea – is it associated with rash severity? Int J Dermatol. 2005;44:372–377.
  • Drago F, Ciccarese G, Rebora A, et al. The efficacy of macrolides and acyclovir in pityriasis rosea. Indian J Dermatol Venereol Leprol. 2015;81:56.
  • Chuh A, Zawar V, Sciallis G, et al. A position statement on the management of patients with pityriasis rosea. J Eur Acad Dermatol Venereol. 2016;30:1670–1681.
  • Zeligman I. Cortisone therapy for pruritic pityriasis rosea. Bull Sch Med Univ Md. 1955;40:76–77.
  • Tay YK, Goh CL. One-year review of pityriasis rosea at the National Skin Centre, Singapore. Ann Acad Med Singap. 1999;28:829–831.
  • Stulberg DL, Wolfrey J. Pityriasis rosea. Am Fam Physician. 2004;69:87–91.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.